MedTrace Logo

Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC

NCT02275806 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2019-08-21

No results posted yet for this study

Summary

This is a prospective, single institution phase II study, whose primary objective is to estimate the median and three year survival rate of non-small lung cancer patients with Stage IIIA and IIIB intra-thoracic disease which is referred to as "locally advanced" non-small cell lung cancer (NSCLC).

Conditions

  • Lung Neoplasms, Non-Small Cell Lung Cancer

Interventions

DRUG

Irinotecan

DRUG

Cisplatin

Sponsors & Collaborators

  • Leo W. Jenkins Cancer Center

    lead OTHER

Principal Investigators

  • Paul Walker, MD, FACP · Brody School of Medicine at East Carolina University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2017-09-27
Completion
2017-09-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02275806 on ClinicalTrials.gov